The identification of new chemotherapeutic agents for the treatment of non-small cell lung cancer should proceed in a structured, logical fashion. Agents should be evaluated on the basis of multiple objective and subjective end points. A 15% or greater major objective response rate, demonstrated in multiple single-agent phase II trials, is considered the lower limit for an agent to be deemed clinically active in this disease. A number of drugs previously have been identified in this category, including cisplatin, ifosfamide, mitomycin, paclitaxel, 3he principles of Karnofsky and Burchenal,l reported in 1949, defined the development of chemotherapeutic agents for the treatment of advanced non-small cell lung cancer (NSCLC) ( Table  1 ). These investigators suggested that only agents with demonstrated anticancer activity could prolong survival, and that drugs recognized as active in a given disease must have reproducible overall response rates. They also urged that a drug's toxicity be considered even from early testing, as curative therapy would probably necessitate combination chemotherapy with added side effects of the other agents in the regimen. These tenets have been applicable to all successful chemotherapy programs in this disease and have guided the stepwise improvements seen in the treatment of advanced NSCLC.2 '3 In NSCLC, a 15% or greater major response rate in multiple single-agent phase II trials is considered the threshold of clinical utility.4 Agents with response rates below this level are unlikely to have a significant impact on symptoms or survival. To date, established active agents include cisplatin, mitomycin, vinblastine, vindesine, ifosfamide, and paclitaxel (Table   2 ). Other commonly used agents like carboplatin, cyclophosphamide, and etoposide have somewhat lower pooled response rates5 (Table 38 Recently, a number of agents have shown promising preclinical or clinical activity or both in NSCLC and may be suitable for combination therapy. These agents under development include chloroquinoxaline sulfonamide (CQS), docetaxel, edatrexate (10-EdAM), gemcitabine, irinotecan (CPT-11), topotecan, and vinorelbine (Table 4) .
CHLOROQUINOXALINE SULFONAMIDE
A sulfanilamide derivative, CQS was the first agent identified as having antitumor activity in the human tumor colony-forming assay (HTCFA).9 Preclinical study has shown that concentrations of the drug associated with activity in the HTCFA were clinically achievable. In a phase I trial of CQS given as a 1-h infusion every 28 days,10 hypoglycemia was identified as the dose-limiting toxicity. A subsequent phase I trial used a weekly administration schedule, defined hypoglycemia at a weekly dose of 2,500 mg/m2 as the Two additional phase IL trials tested docetaxel in both untreated and previously treated NSCLC patients, the latter a notoriously difficult group to treat.14'15 The trial by Burris et 36 patients with advanced NSCLC received 800 mg/mi2 gemcitabine weekly for 3 consecutive weeks followed by 1 week off. Among 29 evaluable patients, 7 major objective responses were reported (24%, 95% CI, 10 to 43%). Individual dose escalation was feasible in about 20% of patients. No World Health Organization (WHO) grade 4 toxicities were seen, and grade 3 transaminase elevation and myelosuppression were seen in less than 1% of administered doses. In a similarly designed trial,26 treatment at doses of 1 g/m2 (53 patients) and 1.25 g/m2 (32 patients) weekly yielded a 20% major response rate including 3% complete responses (CR). Toxicity was similar to that observed in an MD Anderson Center study,27 which treated 21 chemotherapy-naive patients on an identical schedule but enrolled patients at increasing dose levels ranging from 1 g/m2/week to 1.75 g/m2/week. At this highest dose level, hepatotoxicity was dose-limiting. Four of 19 evaluable patients achieved a major response (21%, 95% CI, 6 to 46%).
The largest reported study enrolled 161 patients with NSCLC from European and Canadian centers.28 Treatment commenced at a dose of 1.25 g/m2, and dose escalation was possible in 25% of treatments. A 17% response rate has been reported with 1% CR. WHO grade 3/4 hepatotoxicity occurred in 2% of patients, and 6% experienced grade 3/4 neutropenia. In summary, gemcitabine reliably has produced response rates of 17 to 24% and appears, because of 3 weeks to a 120-h infusion every 3 weeks, and neutropenia is dose-limiting. Based on data in human-mouse xenografts, Hochster and colleagues36 are evaluating topotecan given as a 21-day continuous infusion in a phase I trial. Dose-limiting hematologic toxicity has not been reached in that trial, but the calculated dose intensity already has exceeded that of the recommended phase II dose of 1.5 mg/m2 daily for 5 days. This seemingly favorable hematologic toxicity profile, combined with the opportunity for prolonged drug exposure so as to affect dividing cells at the appropriate stage of the cell cycle, make this an appealing schedule for phase II investigation in NSCLC patients. Phase I studies suggest activity in a variety of diseases in addition to NSCLC, eg, breast, ovarian, and colon carcinomas. However, a phase II trial by Lynch and coworkers,37 in which topotecan was given at a dose of 2 mg/mi2 for 5 days, yielded no objective responses in a group of 20 NSCLC patients who had not received prior chemotherapy. Phase 1I trials in NSCLC using the 21-day continuous infusion schedule are now in progress.
VINORELBINE
Vinorelbine is a hemisynthetic vinca alkaloid recently approved in the United States as a single agent or in combination with cisplatin for the treatment of advanced NSCLC. The compound is structurally modified in the catharanthine (rather than the vindoline) ring, which appears to impart a favorable toxicity and activity profile. Phase II studies have generally used a schedule of 30 mg/mi2 weekly as a single 20-min infusion. An initial phase II trial in NSCLC showed a response rate of 32% (95% CI, 23 to 41%) in 97 patients.38 A subsequent phase II trial39 reported a 29% response rate in 62 evaluable patients. Because of these promising results, randomized single-agent and combination trials were undertaken. In the first,40 a multicenter study, 612 patients were randomized to receive vinorelbine in combination with cisplatin (120 mg/mi2), vinorelbine alone, or vindesine with cisplatin; response rates were 30, 14, and 19%, respectively. Median duration of survival was 40 weeks in the vinorelbine/cisplatin arm, 32 weeks in the vindesine/cisplatin group, and 31 weeks in the vinorelbine arm. Comparison of survival among the groups showed a statistically significant advantage for the vinorelbine/cisplatin group. Neutropenia was significantly higher in the vinorelbine/ cisplatin group, but neurotoxicity occurred more frequently in the vindesine/cisplatin cohort. A second multicenter trial4' randomized patients to receive weekly vinorelbine or 5-fluorouracil (5-FU) (425 mg/M2 daily X5) with leucovorin (20 mg/m2 daily X5). A 12% major response rate was observed in the vinorelbine arm (n=143) vs 6% for the 5-FU/ leucovorin group, a difference not attaining statistical significance. However, median survival for the vinorelbine group (29 weeks) was prolonged vs the 5-FU arm (21 weeks) (p=0.02). These two trials were pivotal in the FDA approval of vinorelbine. Future studies of active agents or combinations thereof will need to be compared with those of vinorelbine or vinorelbine/cisplatin.
COMBINATION DRUG DEVELOPMENT
The development of successful combination chemotherapeutic regimens requires the continued identification of single agents with reproducible response rates above 15%. The toxicity profiles of component agents, together with their mechanisms of action, must be taken into account. Nonoverlapping toxicities and preclinically demonstrated synergism make for the most attractive designs. Importantly, a component drug's dose and schedule should be close to that used in single-agent phase II trial yielding the highest response rates. When optimization of dose or schedule requires supportive care measures such as combination antiemetics and cytokine growth factors, such measures should be used routinely. With the recent identification of a number of new agents with activity in NSCLC, it is likely that novel combinations will be designed with higher response rates and perhaps more prolonged median survival than those of historic controls. However, before dramatic improvements in survival are seen, active chemotherapeutic agents will likely have to be combined tibodies,42 differentiation agents,43 or cytokines44 in logically, scientifically founded programs.
CONCLUSIONS
The incidence and mortality rates for lung cancer continue to increase yearly. Even if prevention methods are intensified, so many individuals have already been exposed to tobacco smoke that we can anticipate this epidemic to continue for decades. The ongoing clinical development of a number of unique agents with activity in advanced NSCLC raises hope that further improvements in symptom control and survival will be realized. Progress in this area is slow and survival benefits achieved to date are measured in months; thus, the need for better therapies is great. Efforts to determine optimal chemotherapeutic combinations using these new agents must continue and expand. Rapid advances in the molecular biology of lung cancer, the understanding and circumvention of drug resistance, and combination therapy design based on in vitro synergy should be incorporated into future trials. Such an approach may allow for a more efficient and logical evaluation of chemotherapeutic programs.
